Literature DB >> 10523798

A strategy for erythropoietin treatment in myelodysplastic syndromes.

R Hast1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10523798     DOI： 10.1007/bf02906130

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


× No keyword cloud information.
  18 in total

1.  Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy.

Authors:  E Estey; P Thall; M Beran; H Kantarjian; S Pierce; M Keating
Journal:  Blood       Date:  1997-10-15       Impact factor: 22.113

2.  Serum levels of tumour necrosis factor-alpha predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome.

Authors:  R Stasi; M Brunetti; S Bussa; M Conforti; L S Martin; M La Presa; M Bianchi; A Parma; A Pagano
Journal:  Clin Lab Haematol       Date:  1997-09

3.  A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in myelodysplastic syndromes.

Authors:  P Bernell; L Stenke; J Wallvik; E Hippe; R Hast
Journal:  Leuk Res       Date:  1996-08       Impact factor: 3.156

4.  Treatment of myelodysplastic syndromes with recombinant human erythropoietin.

Authors:  E Hellström; G Birgegård; D Lockner; C Helmers; A Ost; L Wide
Journal:  Eur J Haematol       Date:  1991-11       Impact factor: 2.997

5.  A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes.

Authors:  E Hellström-Lindberg; G Birgegård; M Carlsson; J Carneskog; I M Dahl; I Dybedal; G Grimfors; K Merk; J M Tangen; I Winqvist
Journal:  Leuk Lymphoma       Date:  1993-10

6.  Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin.

Authors:  P Musto; R Matera; M M Minervini; C Checchia-de Ambrosio; C Bodenizza; A Falcone; M Carotenuto
Journal:  Haematologica       Date:  1994 May-Jun       Impact factor: 9.941

7.  Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies.

Authors:  E Hellström-Lindberg
Journal:  Br J Haematol       Date:  1995-01       Impact factor: 6.998

8.  Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes.

Authors:  L Stenke; J Wallvik; F Celsing; R Hast
Journal:  Leukemia       Date:  1993-09       Impact factor: 11.528

9.  Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients.

Authors:  E Hellström-Lindberg; T Ahlgren; Y Beguin; M Carlsson; J Carneskog; I M Dahl; I Dybedal; G Grimfors; L Kanter-Lewensohn; O Linder; M Luthman; E Löfvenberg; H Nilsson-Ehle; J Samuelsson; J M Tangen; I Winqvist; G Oberg; A Osterborg; A Ost
Journal:  Blood       Date:  1998-07-01       Impact factor: 22.113

Review 10.  Therapeutic aspects of myelodysplastic syndromes in chronic phase.

Authors:  R Hast; E Hellström
Journal:  Leuk Res       Date:  1992       Impact factor: 3.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.